• Cochrane Db Syst Rev · Apr 1996

    Review

    WITHDRAWN: Antiplatelet therapy for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischemic attacks.

    • P J Koudstaal.
    • University Hospital Rotterdam, Department of Neurology, 40 Dr Molewaterplein, Rotterdam, Netherlands, 3015 GD. p.j.koudstaal@erasmusmc.nl
    • Cochrane Db Syst Rev. 1996 Apr 22 (1): CD000186.

    BackgroundPeople with nonrheumatic atrial fibrillation who have had a transient ischemic attack or minor ischemic stroke are at risk of recurrent stroke.ObjectivesThe objective of this review was to assess the effect of antiplatelet therapy for secondary prevention in people with nonrheumatic atrial fibrillation and a previous transient ischaemic attack or ischaemic stroke.Search StrategyThe reviewer searched the Cochrane Stroke Group trials register and contacted trialists.Selection CriteriaRandomised trials comparing an antiplatelet agent with placebo or open control in people with nonrheumatic atrial fibrillation and a previous transient ischaemic attack or minor ischaemic stroke.Data Collection And AnalysisOne reviewer extracted the data.Main ResultsOne trial was included, in which 300 milligrams of aspirin per day was compared with placebo. This review includes 404 aspirin-treated patients and 378 placebo patients in total. The mean follow-up was 2.3 years. No difference was shown between aspirin and placebo in the annual rate of all vascular events, including vascular death, recurrent stroke (ischaemic or haemorrhagic), myocardial infarction, and systemic embolism. The odds ratio was 0.84, 95% confidence interval 0.63 to 1.14, or 15% of those receiving aspirin versus 19% for those given placebo. Aspirin may prevent 40 vascular events (of all types) per 1000 patients treated for one year. There was a non-significant reduction in the risk of recurrent stroke from 12% to 10% per year (odds ratio 0.89, 95% confidence interval 0.64 to 1.24). The incidence of major bleeding events, requiring hospitalisation, blood transfusion or surgical treatment, was low (0.9% per year for aspirin versus 0.7% for placebo).Authors' ConclusionsAspirin may reduce the risk of vascular events in people with nonrheumatic atrial fibrillation, but the effect shown in the single trial was not statistically significant.

      Pubmed     Full text   Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    hide…